Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Inhibrx Announces Participation in Upcoming Scientific Conference PR Newswire - Mon Mar 2, 3:00PM CST

SAN DIEGO , March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 71.86 (+3.87%)
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program PR Newswire - Tue Dec 16, 2025

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 71.86 (+3.87%)
Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire - Fri Nov 14, 2025

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion...

INBX : 71.86 (+3.87%)
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire - Tue Nov 4, 2025

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 71.86 (+3.87%)
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts PR Newswire - Thu Oct 23, 2025

SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 71.86 (+3.87%)
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts PR Newswire - Wed Oct 22, 2025

– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –

INBX : 71.86 (+3.87%)
Inhibrx Reports Second Quarter 2025 Financial Results PR Newswire - Wed Aug 13, 2025

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following...

INBX : 71.86 (+3.87%)
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire - Wed Oct 18, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 71.86 (+3.87%)
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada PR Newswire - Tue Sep 19, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare...

INBX : 71.86 (+3.87%)
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a...

INBX : 71.86 (+3.87%)

Barchart Exclusives

2 High-Yield Dividend Stocks to Buy Now Amid the U.S.-Iran War Barchart - Mon Mar 9, 6:30PM CDT
J.P. Morgan’s more bullish stance on select European majors makes sense here, because Eni and TotalEnergies combine mid‑single‑digit yields, below‑sector valuation multiples, and diversified upstream, downstream, and renewables portfolios that can monetize a sustained Middle East risk premium while still paying investors to wait. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot